Jubilant Pharmova Limited (NSE:JUBLPHARMA)
India
· Delayed Price · Currency is INR 993.80
+4.50 (0.45%)
May 21, 2025, 3:30 PM IST
Jubilant Pharmova Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Net Income | 8,394 | 771 | -610 | 4,139 | 8,359 | Upgrade
|
| Depreciation & Amortization | 3,686 | 3,279 | 3,348 | 2,928 | 3,234 | Upgrade
|
| Other Amortization | - | 540 | 742 | 735.2 | - | Upgrade
|
| Loss (Gain) From Sale of Assets | -13 | -2 | 27 | 33.7 | 70.1 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | 1,450 | 153.83 | 255.81 | Upgrade
|
| Loss (Gain) From Sale of Investments | 17 | -2 | 50 | -1.47 | -29.89 | Upgrade
|
| Loss (Gain) on Equity Investments | 5 | -511 | -123 | 99.83 | -112.52 | Upgrade
|
| Stock-Based Compensation | 43 | 85 | 37 | 11.24 | - | Upgrade
|
| Other Operating Activities | -2,529 | 3,022 | 1,143 | 2,059 | -868.55 | Upgrade
|
| Change in Accounts Receivable | 242 | 494 | 386 | -721.37 | -1,127 | Upgrade
|
| Change in Inventory | 785 | 908 | -647 | -956.47 | 1,343 | Upgrade
|
| Change in Accounts Payable | 553 | 232 | 2,105 | 1.58 | 2,283 | Upgrade
|
| Change in Other Net Operating Assets | -462 | 897 | -1,301 | -106.61 | - | Upgrade
|
| Operating Cash Flow | 10,721 | 9,713 | 6,607 | 8,375 | 17,843 | Upgrade
|
| Operating Cash Flow Growth | 10.38% | 47.01% | -21.11% | -53.06% | 15.64% | Upgrade
|
| Capital Expenditures | -11,156 | -8,977 | -8,145 | -6,000 | -5,275 | Upgrade
|
| Sale of Property, Plant & Equipment | 50 | 97 | 186 | 35.18 | 131.95 | Upgrade
|
| Investment in Securities | 9,507 | -21 | -117 | 2,121 | -2,288 | Upgrade
|
| Other Investing Activities | 6,476 | 2,822 | 2,632 | 40.21 | 41.19 | Upgrade
|
| Investing Cash Flow | 4,877 | -6,079 | -5,444 | -3,804 | -7,390 | Upgrade
|
| Short-Term Debt Issued | 225 | - | 1,943 | 439.99 | - | Upgrade
|
| Long-Term Debt Issued | 49 | 1,172 | 28,104 | 2,032 | 12,301 | Upgrade
|
| Total Debt Issued | 274 | 1,172 | 30,047 | 2,472 | 12,301 | Upgrade
|
| Short-Term Debt Repaid | - | -617 | - | - | -6,299 | Upgrade
|
| Long-Term Debt Repaid | -11,602 | -1,371 | -28,431 | -647.85 | -20,058 | Upgrade
|
| Total Debt Repaid | -11,602 | -1,988 | -28,431 | -647.85 | -26,357 | Upgrade
|
| Net Debt Issued (Repaid) | -11,328 | -816 | 1,616 | 1,824 | -14,056 | Upgrade
|
| Issuance of Common Stock | 9 | - | - | - | - | Upgrade
|
| Repurchase of Common Stock | -56 | -274 | -40 | - | -100.61 | Upgrade
|
| Common Dividends Paid | -796 | -798 | -801 | -800.53 | -14.75 | Upgrade
|
| Other Financing Activities | -2,356 | -2,437 | -2,342 | -1,349 | -2,922 | Upgrade
|
| Financing Cash Flow | -14,527 | -4,325 | -1,567 | -325.99 | -17,094 | Upgrade
|
| Foreign Exchange Rate Adjustments | 248 | 116 | 705 | 572.88 | 122.59 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | - | - | - | -769.81 | Upgrade
|
| Net Cash Flow | 1,319 | -575 | 301 | 4,819 | -7,289 | Upgrade
|
| Free Cash Flow | -435 | 736 | -1,538 | 2,376 | 12,568 | Upgrade
|
| Free Cash Flow Growth | - | - | - | -81.10% | 29.73% | Upgrade
|
| Free Cash Flow Margin | -0.60% | 1.10% | -2.45% | 3.88% | 20.61% | Upgrade
|
| Free Cash Flow Per Share | -2.74 | 4.63 | -9.66 | 14.92 | 78.91 | Upgrade
|
| Cash Interest Paid | - | 2,437 | 2,342 | 1,349 | 2,922 | Upgrade
|
| Cash Income Tax Paid | - | 2,077 | 2,043 | 1,941 | 3,941 | Upgrade
|
| Levered Free Cash Flow | 3,053 | -3,412 | -1,581 | 463.38 | 10,523 | Upgrade
|
| Unlevered Free Cash Flow | 4,555 | -1,810 | -527.02 | 1,327 | 11,606 | Upgrade
|
| Change in Net Working Capital | -6,638 | 6 | -1,148 | 1,596 | -6,493 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.